Close

Ono Pharma to develop KAI Pharma hyperparathyroid drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider.

Related stories

Körber Launches PAS-X Neo MES for Small Pharma Manufacturers

Technology company Körber has introduced a new manufacturing execution...

How Bullying Affects Young People’s Mental Health

Bullying is sometimes brushed off as a normal part...

Supplement Distribution Is a cGMP Problem, Not Just a Logistics One

Three in four U.S. adults take dietary supplements, according...
- Advertisement -

Ono Pharmaceutical has entered into an agreement to develop and commercialize KAI Pharmaceuticals’ lead product candidate KAI-4169 in Japan.

KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease-mineral and bone disorder, is in Phase 2 clinical testing.

As per the agreement, Ono receives rights to all indications for injectable formulations of KAI-4169 in Japan and also retains marketing rights in all other regions.KAI will receive $13m as an upfront payment from Ono and will also receive a royalty on sales.

KAI Pharmaceuticals president and CEO Steven James said they are excited about the continued momentum of the KAI-4169 program, and they anticipate completing the Phase 2 trial and reporting data by the end of this year.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Körber Launches PAS-X Neo MES for Small Pharma Manufacturers

Technology company Körber has introduced a new manufacturing execution...

How Bullying Affects Young People’s Mental Health

Bullying is sometimes brushed off as a normal part...

Supplement Distribution Is a cGMP Problem, Not Just a Logistics One

Three in four U.S. adults take dietary supplements, according...

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »